Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Iseganan (IntraBiotics pharmaceuticals).

Jeffrey H Toney¹

¹Merck Research Laboratories, Rahway, NJ 07065-0900, USA. jeff_toney@merck.com

Current Opinion in Investigational Drugs (London, England : 2000)

|May 22, 2002

Summary

Iseganan is a novel protegrin being developed to treat oral mucositis and other infections. It effectively targets bacteria and fungi by disrupting their cell membranes, offering potential against resistant strains.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Decentralize Egypt's higher education.

Science (New York, N.Y.)·2011

Same author

Societal benefits of network science.

Science (New York, N.Y.)·2011

Same author

Evolving carbapenemases: can medicinal chemists advance one step ahead of the coming storm?

Journal of medicinal chemistry·2010

Same author

Age dependence of glucose tolerance in adult KK-Ay mice, a model of non-insulin dependent diabetes mellitus.

Lab animal·2009

Same author

Purposeful learning with drug repurposing.

Science (New York, N.Y.)·2009

Same author

Oleic acid and peanut oil high in oleic acid reverse the inhibitory effect of insulin production of the inflammatory cytokine TNF-alpha both in vitro and in vivo systems.

Lipids in health and disease·2009

Area of Science:

Antimicrobial drug development
Oncology supportive care
Infectious disease research

Background:

Oral mucositis is a common, debilitating side effect of cancer therapies.
Existing treatments for oral mucositis and related infections have limitations.
Antimicrobial resistance necessitates the development of novel therapeutic agents.

Purpose of the Study:

To evaluate the potential of iseganan (IB-367) as a treatment for oral mucositis.
To explore iseganan's efficacy against a broad spectrum of bacterial and fungal pathogens.
To investigate iseganan's mechanism of action in disrupting microbial cell membranes.

Main Methods:

Iseganan is a protegrin developed by IntraBiotics.
Formulations include rinse, aerosolized liquid, and gel.
Mechanism involves disruption of the lipid cell membrane integrity.

Main Results:

Iseganan demonstrates broad-spectrum activity against bacteria and fungi.
Effective against microbes resistant to conventional antimicrobial drugs.
Potential applications in treating oral mucositis, respiratory infections, and pneumonia.

Conclusions:

Iseganan shows promise as a novel therapeutic agent for various infections.
Its unique mechanism of action may overcome existing antimicrobial resistance.
Further development is warranted for its clinical application in supportive cancer care and infectious diseases.

Related Experiment Videos